Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study”

The totality of evidence favors the efficacy of convalescent plasma to treat COVID-19 when high-titer plasma is administered early in the course of disease or to immunocompromised patients. In this commentary, we frame the findings of L. A. Bartelt, A. J. Markmann, B. Nelson, J. Keys, et al. (mBio 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Joyner, Michael J., Paneth, Nigel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765513/
https://www.ncbi.nlm.nih.gov/pubmed/36314790
http://dx.doi.org/10.1128/mbio.02653-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765513/
https://www.ncbi.nlm.nih.gov/pubmed/36314790
http://dx.doi.org/10.1128/mbio.02653-22

Ejemplares similares